Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis

Condition:   Desmoid-Type FibromatosisInterventions:   Other: Laboratory Biomarker Analysis;   Other: Placebo;   Other: Quality-of-Life Assessment;   Drug: Sorafenib TosylateSponsor:   National Cancer Institute (NCI)Recruiting - verified March 2015
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials